Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors?

Molecular and Cellular Endocrinology

Volumn 277, Issue 1-2, 2007, Pages 6-12

  Grossmann, Claudia ^a   Gekle, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Aldosterone; EGF receptor; Mineralocorticoid receptor; Renocardiovascular remodelling; Vascular smooth muscle cell

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POTASSIUM CHANNEL; PROTEIN TYROSINE KINASE; SODIUM CHANNEL;

ADRENAL CORTEX; CARDIOVASCULAR SYSTEM; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVATION; FIBROSIS; GENOME ANALYSIS; HUMAN; KIDNEY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REPORTER GENE; REVIEW; SODIUM RETENTION; UPREGULATION; VASCULAR DISEASE; ZONA GLOMERULOSA;

ALDOSTERONE; ANIMALS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, MINERALOCORTICOID;

EID: 34848842134     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.07.001     Document Type: Review

References (60)

1. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., and Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237 (1987) 268-275
2. Asakura M., Kitakaze M., Takashima S., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8 (2002) 35-40
3. Bokemeyer D., Schmitz U., and Kramer H.J. Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int. 58 (2000) 549-558
4. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., Miller W.T., and Edwards D.P. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell 8 (2001) 269-280
5. Braun S., Lösel R.M., Wehling M., and Boldyreff B. Aldosterone rapidly activates Src kinase in M-1 cells involving the mineralocorticoid receptor and HSP84. FEBS Lett. 570 (2004) 69-72
6. Brilla C.G., and Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120 (1992) 893-901
7. Callera G.E., Touyz R.M., Tostes R.C., Yogi A., He Y., Malkinson S., and Schiffrin E.L. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45 (2005) 773-779
8. Callera G.E., Montezano A.C.I., Yogi A., Tostes R.C., He Y., Schiffrin E.L., and Touyz R.M. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46 (2005) 1032-1038
9. Doolan C.M., and Harvey B.J. Modulation of cytosolic protein kinase C and calcium ion activity by steroid hormones in rat distal colon. J. Biol. Chem. 271 (1996) 8763-8767
10. Dorrance A.M., Osborn H.L., Grekin R., and Webb R.C. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001) R944-R950
11. Flamant M., Tharaux P.L., Placier S., Henrion D., Coffman T., Chatziantoniou C., and Dussaule J.C. Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J. 17 (2003) 327-329
12. Florian J.A., Dorrance A., Webb R.C., and Watts S.W. Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001) R878-R886
13. Funder J.W. Is aldosterone bad for the heart?. Trends Endocrinol. Metab. 15 (2004) 139-142
14. Funder J.W. Aldosterone and mineralocorticoid receptors. Lessons from gene deletion studies. Hypertension 48 (2006) 1018-1019
15. Funder J.W. Mineralocorticoid receptors and cardiovascular damage. It's not just aldosterone. Hypertension 47 (2006) 634-635
16. Funder J.W. Aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 147 (2006) 5564-5567
17. 2+ and stimulation of a plasma membrane proton conductance. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10500-10504
18. +-exchange in MDCK-cells by aldosterone involves MAP-kinases ERK1/2. Pflügers Arch. 441 (2001) 781-786
19. Gekle M., Freudinger R., Mildenberger S., and Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am. J. Physiol. Renal Physiol. 282 (2002) F669-F679
20. Gekle M., Freudinger R., Mildenberger S., and Silbernagl S. Rapid actions of aldosterone on cells from renal epithelium: the possible role of EGF-receptor signaling. Steroids 67 (2002) 499-504
21. Gekle M., Mildenberger S., Freudinger R., and Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pflügers Arch. 454 (2007) 403-413
22. Goodfriend T.L. Aldosterone-a hormone of cardiovascular adaptation and maladaptation. J. Clin. Hypertens. 8 (2006) 133-139
23. + reabsorption. Am. J. Physiol. Renal Physiol. 286 (2004) F1226-F1231
24. Grossmann C., Benesic A., Krug A.W., Freudinger R., Mildenberger S., Gassner B., and Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 19 (2005) 1697-1710
25. Grossmann C., Krug A.W., Freudinger R., Mildenberger S., Volker K., and Gekle M. Aldosterone-induced epidermal growth factor receptor (EGFR) expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am. J. Physiol. Endocrinol. Metab. 292 (2007) 1790-1800
26. Hackel P.O., Zwick E., Prenzel N., and Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11 (1999) 184-189
27. Hunyady L., and Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 20 (2006) 953-970
28. Jaffe I.Z., and Mendelsohn M.E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96 (2005) 643-650
29. Kagiyama S., Eguchi S., Frank G.D., Inagami T., Zhang Y.C., and Phillips M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106 (2002) 909-912
30. Kagiyama S., Qian K., Kagiyama T., and Phillips M.I. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41 (2003) 824-829
31. Krug A.W., Schuster C., Gassner B., Freudinger R., Mildenberger S., Troppmair J., and Gekle M. Human EGF receptor 1 (HER1) expression renders CHO cells sensitive to alternative aldosterone signalling. J. Biol. Chem. 277 (2002) 45892-45897
32. Krug A.W., Grossmann C., Schuster C., Freudinger R., Mildenberger S., Govindan M.V., and Gekle M. Aldosterone stimulates epidermal growth factor receptor (EGFR) expression. J. Biol. Chem. 278 (2003) 43060-43066
33. Le Moellic C., Ouvrard-Pascaud A., Capurro C., Cluzeaud F., Fay M., Jaisser F., Farman N., and Blot-Chabaud M. Early nongenomic events in aldosterone action in renal collecting duct cells: PKCalpha activation mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J. Am. Soc. Nephrol. 15 (2004) 1145-1160
34. Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., and Feldman R.D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108 (2003) 2400-2406
35. Mazak I., Fiebeler A., Muller D.N., et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109 (2004) 2792-2800
36. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., Gong W., Beato M., and Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17 (1998) 2008-2018
37. Migliaccio A., Castoria G., Di Domenico M., et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 19 (2000) 5406-5417
38. Mihailidou A.S., Mardini M., and Funder J.W. Rapid nongenomic effects of aldosterone in the heart mediated by ε protein kinase C. Endocrinology 145 (2004) 773-780
39. Min L.J., Mogi M., Li J.M., Iwanami J., Iwai M., and Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ. Res. 97 (2005) 434-442
40. Moghal N., and Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11 (1999) 190-196
41. Nakano S., Kobayashi N., Yoshida K., Ohno T., and Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens. Res. 28 (2005) 925-936
42. Neithardt A., Farshori M.P., Shah F.B., Catt K.J., and Shah B.H. Dependence of GnRH-induced phosphorylation of CREB and BAD on EGF receptor transactivation in GT1-7 neuronal cells. J. Cell Physiol. 208 (2006) 586-593
43. Northcott C., Florian J.A., Dorrance A., and Watts S.W. Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension 38 (2001) 1337-1341
44. Park J.B., and Schiffrin E.L. ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37 (2001) 1444-1449
45. 2 modulates GRE-element activation by the human mineralocorticoid receptor in HEK cells. Mol. Cell Endocrinol. 264 (2007) 35-43
46. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 108 (2003) 1790-1794
47. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999) 709-717
48. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003) 1309-1321
49. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., and Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 (1999) 884-888
50. Pu Q., Neves M.F., Virdis A., Touyz R.M., and Schiffrin E.L. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42 (2003) 49-55
51. Pullar C.E., and Isseroff R.R. The {beta}2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms. J. Cell Sci. 119 (2006) 592-602
52. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak D.A., Kekec B.K., Blomme E.A.G., McMahon E.G., and Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. AJP-Heart Circ. Physiol. 283 (2002) H1802-H1810
53. Shah B.H., and Catt K.J. A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol. Sci. 24 (2003) 239-244
54. Shen J.P., and Cotton C.U. Epidermal growth factor inhibits amiloride-sensitive sodium absorption in renal collecting duct cells. Am. J. Physiol. Renal Physiol. 284 (2003) F57-F64
55. Sugiyama T., Yoshimoto T., Tsuchiya K., Gochou N., Hirono Y., Tateno T., Fukai N., Shichiri M., and Hirata Y. Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146 (2005) 3900-3906
56. Terzi F., Burtin M., Hekmati M., Federici P., Grimber G., Briand P., and Friedlander G. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J. Clin. Invest. 106 (2000) 225-234
57. Thomas W.G., Brandenburger Y., Autelitano D.J., Pham T., Qian H., and Hannan R.D. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ. Res. 90 (2002) 135-142
58. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
59. Wetzker R., and Bohmer F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell Biol. 4 (2003) 651-657
60. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000) 2700-2706